Subscribe
Core coverageCLDX

Company profile / CLDX

Celldex Therapeutics

Clinaptis stanceCautious
ConvictionMedium
Ticker
CLDX
Exchange
NASDAQ
Coverage
Standard profile
Updated
Aug 19, 2026
Oncology / Immunology

Clinical-stage biotechnology company focused on developing precision-engineered antibodies for cancer and inflammatory diseases.

01 / Clinaptis view

The current read

Pipeline is heavily weighted toward barzolvolimab in chronic spontaneous urticaria (CSU), with optionality in oncology assets like feladilimab.

02 / Consensus gap

Where the market may differ

Regulatory probability and commercial market size for barzolvolimab in CSU vs. development costs.

Coverage state
Standard profile
What the review turns on
Key variable

Regulatory outcome

Next catalyst

Barzolvolimab · Phase 3 CSU topline data · Sept/Oct 2026

03 / Pipeline

Key programs

2 assets · 2 programs

AssetIndicationStageNext event
Barzolvolimab (CDX-0159)
Chronic Spontaneous Urticaria
Phase 3
Phase 3 topline data and NDA preparation
Feladilimab (CDX-301)
Advanced solid tumors
Phase 1/2
Dose expansion updates
04 / Connected research

Published on CLDX

View full archive
  1. 01

    Celldex: A Positive CSU Readout May Not Be Enough

    The p-value looks de-risked. Valuation hinges on whether complete response (CR) looks more like remibrutinib (~28–31%) or clears Xolair’s historical ~34–44% range.

    Read